September 2024 in “Archives of Medical Science” Alopecia areata is linked to immune system differences, with specific biomarkers like CXCL9 and CXCL10 being key for diagnosis and potential treatment targets.
July 2024 in “LA CIENCIA AL SERVICIO DE LA SALUD Y NUTRICIÓN” The condition is harmless, doesn't worsen, and needs no invasive treatment.
July 2024 in “Journal of Investigative Dermatology” Expanding regulatory T cells may help treat alopecia areata by reducing harmful immune cells.
July 2024 in “LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)” Adipose tissue and eccrine gland displacement are common in certain alopecias but don't help differentiate between them.
Combining pentoxifylline with corticosteroids improves alopecia areata treatment.
May 2024 in “The Journal of Immunology” Alopecia Areata can develop without perforin-mediated cytolysis.
March 2024 in “Dermatology and therapy” AA patients with comorbid conditions face more severe hair loss and need specific treatments.
September 2023 in “Cureus” Early recognition and treatment of atypical alopecia areata in infants are crucial.
July 2023 in “The Egyptian Journal of Hospital Medicine ” Alopecia areata is a hair loss condition caused by immune factors and can be treated with JAK inhibitors.
June 2023 in “JAAD Case Reports” A man had a rare skin cancer that looked like a bald spot.
April 2023 in “Revista colombiana de reumatología” JAK inhibitors like tofacitinib can effectively treat severe alopecia areata.
Low-level laser therapy reduces symptoms and inflammation in frontal fibrosing alopecia.
April 2022 in “Indexia revista médico - científica” Alopecia causes sudden hair loss, possibly due to genetic, environmental, or immune factors.
December 2021 in “Journal of clinical images and medical case reports” Moth-eaten alopecia is linked to various skin diseases and requires early treatment to prevent worsening.
September 2021 in “Clinical research in dermatology” 5-Alpha-Reductase inhibitors might help slow down hair loss in Frontal Fibrosing Alopecia but are not a primary treatment and need more research.
July 2021 in “Anais brasileiros de dermatologia/Anais Brasileiros de Dermatologia” Monilethrix causes different levels of hair loss in family members.
June 2020 in “Medicina estética (Madrid)” Female pattern hair loss is common and should be treated early to prevent worsening, with Minoxidil being the main approved treatment.
April 2017 in “Journal of Investigative Dermatology” Reduced Stx17 expression may contribute to Alopecia Areata.
July 2015 in “Journal of the Dermatology Nurses’ Association” A 66-year-old woman experienced hair loss due to Frontal Fibrosing Alopecia, a condition with no consistently effective treatment, but it usually stabilizes over time. More research is needed for better understanding and treatment options.
March 2012 in “Journal of The American Academy of Dermatology” Temporal triangular alopecia usually starts in early childhood and treatment with Minoxidil has limited effectiveness.
18 citations
,
October 2012 in “Dermatologic Clinics” Early diagnosis and aggressive treatment are key for managing rare scalp disorders that cause permanent hair loss.
17 citations
,
June 2016 in “Australasian Journal of Dermatology” Treatment with dutasteride, minoxidil, and artificial hair transplantation improved appearance but caused folliculitis.
16 citations
,
November 2005 in “Journal of Investigative Dermatology Symposium Proceedings” Blocking interferon-gamma helps prevent and treat hair loss in Alopecia Areata.
15 citations
,
November 2012 in “International Journal of Dermatology” The conclusion is that hair loss from CCCA may be genetic and not solely caused by hair grooming practices.
June 2024 in “Computational and Structural Biotechnology Journal” Multi-omics techniques help understand the molecular causes of androgenetic alopecia.
Alopecia Areata has no cure, treatments are limited, and the condition often recurs, but new therapies like JAK inhibitors show promise.
21 citations
,
October 2017 in “Journal of the European Academy of Dermatology and Venereology” Various potential triggers may be causing the rise in frontal fibrosing alopecia, and avoiding these could help stop the disease's increase.
18 citations
,
November 2012 in “Australasian Journal of Dermatology” A 66-year-old man with a rare case of male frontal fibrosing alopecia did not regrow hair despite treatment.
8 citations
,
October 2024 in “Cochrane Database of Systematic Reviews” Tolvaptan can slow kidney disease progression, but doesn't affect mortality or kidney failure.
January 2014 in “Repository KITopen (Karlsruhe Institute of Technology)” The study on Alopecia Areata (AA), a T-cell-mediated autoimmune disease of the hair follicle, identified keratins as autoantigens and explored the mechanism of CD44 and CD44v10 blockade. Vaccination with keratins in mice induced mild AA and significantly increased keratin-specific T-cells. However, when applied in a tolerogenic form, it delayed AA progression by inducing anergy in keratin-specific T-cells and expanding regulatory T-cells.